Document is current

Any future updates will be listed below

Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

Crossref DOI link: https://doi.org/10.1007/s40258-022-00734-z

Published Online: 2022-04-20

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark